Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Clinical Trial

Official title:

An Open-Label Phase II Dose Optimization Study of Bosutinib at a Starting Dose of 300 Mg Daily for Adult Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase Post Frontline TKI Failure

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02906696
• Other study ID #: 2016-0081
• Secondary ID: NCI-2016-0195420
• Status: Terminated
• Phase: Phase 2
• Start date: October 28, 2016
• Est. completion date: August 8, 2019

Study information

• Verified date: April 2020
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Description:

PRIMARY OBJECTIVES:

I. To assess the response rate within 24 weeks in patients in chronic phase receiving bosutinib with the starting dose of 300 mg per day, with potential escalation to 400 mg, 500 mg and 600 mg per day.

SECONDARY OBJECTIVES:

I. Safety of dosing schedule. II. Frequency of treatment interruptions and dose reductions. III. Determine the rate of BCR-ABL/ABL < 10% at 3 months and < 1% at 6 months on the international scale and the rate of complete cytogenetic response (CCyR) at 6 months after the start of treatment.

IV. Determine the cumulative rate of CCyR. V. Determine the rate of major molecular response, molecular response (MR)4, MR4.5 and complete molecular response.

VI. Determine long-term outcomes, including progression-free survival, event-free survival, and overall survival.

VIII. Investigate the correlation between ABL kinase domain mutations, if present at the time of enrollment, with outcome.

IX. Determine the rate of development and type of ABL kinase domain mutations during therapy with bosutinib.

OUTLINE:

Patients receive bosutinib orally (PO) daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for up to 2 years, every 24 weeks for 2 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: August 8, 2019
• Est. primary completion date: August 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with chronic myeloid leukemia (CML) in chronic phase who have resistance and/or intolerance to frontline TKI therapy; resistance is defined as lack (lack defined as response not achieved or lost by the given dates mentioned hereafter) of CHR (complete hematologic response) within 3 months, lack of major cytogenetic response (MCyR) within 6 months, and lack of CCyR within 12 months of therapy with frontline TKIs; in addition, loss of MCyR, CCyR or MMR at any time during the course of therapy is also considered resistance to therapy; intolerance is defined as persistent or severe toxicity that is unacceptable to the patient

• Chronic phase disease is defined as:

• < 15% blasts in peripheral blood and bone marrow;

• < 30% blasts plus promyelocytes in peripheral blood and bone marrow;

• < 20% basophils in peripheral blood;

• >= 100 x 10^9/L platelets (>= 100,000/mm^3);

• No evidence of extramedullary disease except hepatosplenomegaly; and

• No prior diagnosis of accelerated phase (AP) or blastic phase-chronic myeloid leukemia (BP-CML); patients with clonal evolution but no other criteria for accelerated phase are eligible

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• Creatinine less than or equal to 2.0 mg/dl

• Bilirubin less than or equal to 2.0 mg/dl

• Alanine aminotransferase (ALT) less than or equal to 3 times institutional upper limit of normal

• Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and for 30 days following the last dose of study drug; effective methods of birth control include:

• Birth control pills, shots or implants (placed under the skin by a health care provider) or patches (placed on the skin);

• Intrauterine devices (IUDs);

• Condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicide; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy

• Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug

• Patients or their legally authorized representative must provide written informed consent

Exclusion Criteria:

• Women who are pregnant or lactating

• Known to be human immunodeficiency virus (HIV)+

• Active and uncontrolled disease/infection that in the opinion of the treating physician and principal investigator may affect the ability to participate in the trial or put the patient at unduly high risk

• Unable or unwilling to sign the informed consent document

• Received no other investigational therapy within the past 14 days

• Presence of T315I mutation by ABL1 sequencing

• Patient is currently in complete cytogenetic remission (CCyR)

Related Conditions & MeSH terms

• Blasts Under 15 Percent of Bone Marrow Nucleated Cells
• Blasts Under 15 Percent of Peripheral Blood White Cells
• Blasts Under 30 Percent of Bone Marrow Nucleated Cells
• Blasts Under 30 Percent of Peripheral Blood White Cells
• Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase

Intervention

Drug:
• Bosutinib
Given PO

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI), Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	Response is defined as follows: 1) For patients who do not currently have a partial cytogenetic response (PCyR), achievement of major cytogenetic response is considered a response. 2) For patients who are currently in PCyR, achievement of CCyR is considered a response. The Simon's optimal two-stage design will be used for interim futility monitoring. Will be estimated along with the 95% credible interval.	Up to 6 months
Secondary	Number of Participants With Treatment Interruptions and Dose Reductions	Will be summarized.	Up to 2 years
Secondary	Rates of Major Molecular Response (MR), MR4, MR4.5 and Complete Molecular Response	Will be estimated along with the exact 95% confidence intervals. Molecular assessments are based on quantitative reverse transcriptase polymerase chain reaction for Bcr-Abl in peripheral blood. Molecular response is categorized as MMR (Bcr-Abl/Abl ratio of	Up to 2 years
Secondary	Rates of BCR-ABL/ABL <10%	Will be assessed using the international scale. Will be estimated along with the exact 95% confidence intervals.	At 3 months
Secondary	Rates of BCR-ABL/ABL < 1%	Will be assessed using the international scale. Will be estimated along with the exact 95% confidence intervals.	At 6 months
Secondary	Overall Survival	Will be assessed by Kaplan-Meier methods. Cox proportional hazards regression models will be fit to assess the association between patient characteristics including survival outcome. Time from date of treatment start until date of death due to any cause or last Follow-up.	Up to 2 years
Secondary	Event-free Survival	Time from date of treatment start until the date of first objective documentation of disease-relapse.	Up to 2 years
Secondary	Transformation-free Survival	Will be assessed by Kaplan-Meier methods. Transformation-free survival is defined as the time from treatment initiation until either progression to AP/BP or death from any cause.	Up to 2 years
Secondary	Change of ABL Kinase Domain Mutation Status	Will be summarized and its association with survival outcomes will be analyzed through landmark analyses. Cox proportional hazards regression models will be fit to assess the association between patient characteristics including ABL kinase domain mutation status.	Baseline up to 2 years

External Links

•   University of Texas MD Anderson Cancer Center Website